<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122138">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01512667</url>
  </required_header>
  <id_info>
    <org_study_id>0822-067</org_study_id>
    <nct_id>NCT01512667</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)</brief_title>
  <official_title>A Single Dose Study to Investigate the Pharmacokinetics of Odanacatib (MK-0822) in Subjects With Renal Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate and compare pharmacokinetics of a single 50 mg dose of
      odanacatib administered to participants with impaired renal/kidney function to those of a
      healthy matched control group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve from Zero (0) Hours to Infinity (AUC (0-∞)) After Single Dose MK-0822</measure>
    <time_frame>0 hour to 336 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (C (max)) After Single Dose MK-0822</measure>
    <time_frame>0 hour to 336 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (T (max)) After Single Dose MK-0822</measure>
    <time_frame>0 hour to 336 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-Life (t (½)) After Single Dose MK-0822</measure>
    <time_frame>0 hour to 336 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Severe Renal Insufficiency Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Matched Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0822</intervention_name>
    <description>1 single, oral dose (50 milligram [mg] tablet) of MK-0822 will be administered on Day 1.</description>
    <arm_group_label>Severe Renal Insufficiency Group</arm_group_label>
    <arm_group_label>Healthy Matched Control Group</arm_group_label>
    <other_name>odanacatib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Not currently pregnant, nursing or planning to be pregnant

        through-out the course of the study; individual agrees to use specified contraception per
        protocol requirement for duration of study. Note: All females must have a serum pregnancy
        test to ensure and document negative test results prior to inclusion in the study.

          -  Body Mass Index (BMI) of up to 39.49kg/m^2

          -  Assessed to be in good health, including no clinically significant cardiac
             abnormalities based on results from an electrocardiogram (ECG, performed at
             pre-screening and/or prior to administration of study drug.

          -  Meets the requirements of the study in regard to current medication profile
             including: prescribed medications, caffeine, alcohol, over-the-counter drugs, herbals
             and nutritional products; with expected non-use of recreational (illicit) drugs
             associated with misuse, abuse and/or addiction.

          -  Agrees to adhere to all smoking and dietary restrictions associated with the study.

          -  Possess the ability to understand the study, grant voluntary

        informed consent, and willingly comply with all study requirements.

        Inclusion Criterion Specific to Participants with Renal/Kidney Insufficiency:

          -  Creatinine clearance of &lt;30 mL/min

        Inclusion Criterion Specific to Healthy Volunteers:

          -  Creatine clearance of ≥ 90 mL/min (for healthy volunteers)

        Exclusion Criteria:

          -  Does not meet the age requirement, is mentally or legally incapacitated, has or is
             expected to have significant emotional problems, and/or a history of a clinically
             significant psychiatric disorder.

          -  Diagnosed with a disease or medical condition which may pose a risk to the
             participant or may confound the study results.

          -  Has demonstrated or suspected stenosis (narrowing) of the renal artery, and/or has
             had a renal transplant and/or kidney removal.

          -  Has current, unstable, significant organ system disease(s) and/or cancer(s).

          -  Has had a surgical procedure, donated 1 unit of blood or received another

        investigational study medication within 4 weeks prior to the study's first dose of
        investigational product.

          -  Unable to refrain from or anticipates the use of any new medication, including
             prescription and non-prescription drugs and/or herbal remedies. Exceptions may
             include medications prescribed for prevention of disease or preservation of a healthy
             life.

          -  Uses any medication or agent that has the potential to significantly alter
             renal/kidney function.

          -  Unable to avoid taking diuretics (within 4 hours prior to and after dosing with the
             investigational product)or phosphate binders containing aluminum, calcium or
             lanthanum salts; iron supplements or other metal cations; antacids; or multivitamins
             containing iron or zinc (within 8 hours prior to dosing and 4 hours after dosing with
             the investigational product). Note: individuals prescribed to diuretics must be on a
             stable dose for at least 4 weeks prior to the study's start date in order to
             participate.

          -  History of multiple and/or severe allergies, has had a life-threatening

        reaction to a drug or other agent, and/or inability to tolerate prescription or
        nonprescription drugs and/or food.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 3, 2016</lastchanged_date>
  <firstreceived_date>January 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
